Medtronic, Inc. today announced the launch of a landmark clinical trial for a new heart-failure device that combines the capabilities of an implantable cardioverter defibrillator (ICD) with a new technology that continuously records pressure inside the heart, and can alert physicians to potential heart-failure complications before they worsen.
Genetic Engineering News